Asset-centric SPVs can prove to be a mechanism by which to develop and manage an IP-rich asset over a short period for a profit. In this month's lead article, Daniel Rooke examines the benefits and disadvantages in using Asset-Centric SPVs and the procedural steps behind setting one up.
A legal toolkit for life sciences companies and their investors providing access to information on:
Diana Heimhalt provides an update in respect of the EMA's decision to agree a policy on the publication of clinical trial data... read more
Anja Lunze provides insight into infringement of second medical use claims and an overview of the current debate surrounding the issue in Germany... read more
Receive our monthly newsletter keeping you updated on recent developments and events in the Life Sciences sector...